Attrition in the pharmaceutical industry
Subtitle: reasons, implications, and pathways forward
By: edited by Alexander A. Alex, C. John Harris, Dennis A. Smith
Contributors: Harris, C. John, editor; Smith, Dennis A., editor
Publisher: John Wiley & Sons
Published: 2015
Place of publication: Hoboken, New Jersey
Language: eng
ISBN-13: 9781118679678
Subjects: Pharmaceutical industry; Industrial efficiency; Management; Capital productivity; Drug development
Notes: Includes index.
Table of contents: title: Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis; title: Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop; title: Attrition in phase I / Dennis A. Smith and Thomas A. Baillie; title: Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith; title: Post-marketing attrition / Dennis A. Smith; title: Influence of the regulatory environment on attrition / Robert T. Clay; title: Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt; title: Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy; title: Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams; title: In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis; title: Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale; title: Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.